{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:18:13Z","timestamp":1787969893048,"version":"build-2784847793"},"reference-count":23,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Extent of resection (EOR) has previously been demonstrated to have an impact on survival in patients with glioblastoma (GBM). However, with the World Health Organization (WHO) 2021 reclassification of GBMs based on IDH-mutation status, patients with \"IDH-mutant GBMs,\" who typically survive long term, were reclassified as WHO grade 4 IDH-mutant astrocytomas and removed from the GBM taxonomy. Therefore, it is unknown whether the previously reported impact of resection on survival was a false-positive result due to the inclusion of the less aggressive IDH-mutant tumors in previous datasets. This study aimed to determine the extent to which EOR remains an independent predictor of survival in patients with WHO 2021 GBM after the reclassification of IDH-mutant grade 4 astrocytomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>All cases of GBM tumors (based on the pre-2021 GBM classification) that were newly diagnosed between 2005 and 2021 were identified in our institutional database and subsequently reclassified based on the updated WHO 2021 criteria using IDH status. Multivariable statistical analyses of demographic information, survival time, and EOR based on volumetric MRI were performed to determine the independent predictors of survival for the whole group of patients and for IDH-wildtype GBM patients exclusively. Additional analyses were performed to identify an EOR threshold for improvement in survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 523 tumors classified as GBM based on the pre-2021 taxonomy, 52 (9.9%) cases were reclassified as WHO grade 4 IDH-mutant astrocytomas, and the median survival of patients in this group was 7.9 years, whereas median survival of the IDH-wildtype GBM patients was 1.4 years. Multivariate analyses of the whole group demonstrated that IDH-mutant astrocytomas were associated with reduced hazard of death. In both the whole group (n = 523) and in IDH-wildtype GBMs (n = 471), higher EOR of the contrast-enhancing (CE) tumor was associated with reduced hazard of death, whereas older age or male sex was associated with increased hazard of death. Because most patients (90%) had high EOR values (&gt; 81%), a statistically meaningful EOR threshold could not be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>These analyses demonstrated that EOR of the CE tumor is an independent predictor of survival and that greater EOR is associated with improved survival in WHO 2021 IDH-wildtype GBMs even after excluding grade 4 IDH-mutant astrocytomas. However, an absolute EOR threshold below which resection did not improve survival could not be established, raising concerns about prior cutoff assessments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3171\/2026.1.jns25467","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:12:58Z","timestamp":1782864778000},"page":"1-11","source":"Crossref","is-referenced-by-count":0,"title":["Extent of resection as an independent predictor of survival for patients with glioblastoma as defined by the new WHO 2021 classification"],"prefix":"10.3171","author":[{"given":"Michael P.","family":"Catalino","sequence":"first","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Suki","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leomar","family":"Ballester","sequence":"additional","affiliation":[{"name":"Neuropathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark R.","family":"Andersen","sequence":"additional","affiliation":[{"name":"Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Ramadoss","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujit S.","family":"Prabhu","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice C.","family":"Poon","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip Cem","family":"Cezayirli","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bledi","family":"Brahimaj","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"McCutcheon","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherise D.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibawanye I.","family":"Ene","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty Y. S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaan M.","family":"Raza","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Demonte","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick F.","family":"Lang","sequence":"additional","affiliation":[{"name":"Departments of Neurosurgery,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"issue":"2","key":"b1","series-title":"J Neurosurg","first-page":"190","article-title":"A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival","volume":"95","author":"Lacroix M","year":"2001","unstructured":"Lacroix M, Abi-Said D, Fourney DR,  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190\u2013198. doi:10.3171\/jns.2001.95.2.0190"},{"issue":"11","key":"b2","series-title":"JAMA Oncol","first-page":"1460","article-title":"Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis","volume":"2","author":"Brown TJ","year":"2016","unstructured":"Brown TJ, Brennan MC, Li M,  Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460\u20131469. doi:10.1001\/jamaoncol.2016.1373"},{"issue":"1","key":"b3","series-title":"J Neurosurg","first-page":"3","article-title":"An extent of resection threshold for newly diagnosed glioblastomas: clinical article","volume":"115","author":"Sanai N","year":"2011","unstructured":"Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg. 2011;115(1):3\u20138. doi:10.3171\/2011.2.jns10998"},{"key":"b4","series-title":"World Neurosurg","first-page":"330","article-title":"Prognostic implications of extent of resection in glioblastoma: analysis from a large database","volume":"103","author":"Trifiletti DM","year":"2017","unstructured":"Trifiletti DM, Alonso C, Grover S, Fadul CE, Sheehan JP, Showalter TN. Prognostic implications of extent of resection in glioblastoma: analysis from a large database. World Neurosurg. 2017;103:330\u2013340. doi:10.1016\/j.wneu.2017.04.035"},{"issue":"4","key":"b5","series-title":"JAMA Oncol","first-page":"495","article-title":"Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma","volume":"6","author":"Molinaro AM","year":"2020","unstructured":"Molinaro AM, Hervey-Jumper S, Morshed RA,  Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495\u2013503. doi:10.1001\/jamaoncol.2019.6143"},{"issue":"3","key":"b6","series-title":"Neurosurgery","first-page":"423","article-title":"Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit","volume":"45","author":"Black PM","year":"1999","unstructured":"Black PM, Alexander E, Martin C,  Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. Neurosurgery. 1999;45(3):423-433. doi:10.1097\/00006123-199909000-00001"},{"issue":"11","key":"b7","series-title":"Lancet Oncol","first-page":"1062","article-title":"Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review","volume":"12","author":"Kubben PL","year":"2011","unstructured":"Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062\u20131070. doi:10.1016\/S1470-2045(11)70130-9"},{"issue":"5","key":"b8","series-title":"Lancet Oncol","first-page":"392","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer W","year":"2006","unstructured":"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392\u2013401. doi:10.1016\/S1470-2045(06)70665-9"},{"issue":"1","key":"b9","series-title":"Acta Neuropathol Commun","first-page":"156","article-title":"The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas","volume":"7","author":"Christians A","year":"2019","unstructured":"Christians A, Adel-Horowski A, Banan R,  The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathol Commun. 2019;7(1):156. doi:10.1186\/s40478-019-0817-0"},{"issue":"5897","key":"b10","series-title":"Science","first-page":"1807","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons DW","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X,  An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807\u20131812. doi:10.1126\/science.1164382"},{"issue":"10","key":"b11","series-title":"Nat Rev Clin Oncol","first-page":"645","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi CJ","year":"2021","unstructured":"Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol. 2021;18(10):645\u2013661. doi:10.1038\/s41571-021-00521-0"},{"issue":"6","key":"b12","series-title":"Cancer Cell","first-page":"773","article-title":"Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion","volume":"28","author":"Tateishi K","year":"2015","unstructured":"Tateishi K, Wakimoto H, Iafrate AJ,  Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell. 2015;28(6):773\u2013784. doi:10.1016\/j.ccell.2015.11.006"},{"issue":"8","key":"b13","series-title":"N Engl J Med","first-page":"765","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan H","year":"2009","unstructured":"Yan H, Parsons DW, Jin G,  IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765\u2013773. doi:10.1056\/NEJMoa0808710"},{"issue":"8","key":"b14","series-title":"Neuro Oncol","first-page":"1231","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis DN","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P,  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231\u20131251. doi:10.1093\/neuonc\/noab106"},{"issue":"1","key":"b15","series-title":"Neuro Oncol","first-page":"81","article-title":"IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection","volume":"16","author":"Beiko J","year":"2014","unstructured":"Beiko J, Suki D, Hess KR,  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol. 2014;16(1):81\u201391. doi:10.1093\/neuonc\/not159"},{"key":"b16","series-title":"Front Oncol","first-page":"1087","article-title":"The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma","volume":"10","author":"Incekara F","year":"2020","unstructured":"Incekara F, Smits M, van der Voort SR,  The association between the extent of glioblastoma resection and survival in light of MGMT promoter methylation in 326 patients with newly diagnosed IDH-wildtype glioblastoma. Front Oncol. 2020;10:1087. doi:10.3389\/fonc.2020.01087"},{"key":"b17","series-title":"World Neurosurg.","first-page":"e524","article-title":"Effect of extent of resection on survival of patients with glioblastoma,","volume":"171","author":"Jusue-Torres I","year":"2023","unstructured":"Jusue-Torres I, Lee J, Germanwala AV, Burns TC, Parney IF. Effect of extent of resection on survival of patients with glioblastoma,. IDH-wild-type, WHO grade 4 (WHO 2021): systematic review and meta-analysis. World Neurosurg.2023;171:e524\u2013e532. doi:10.1016\/j.wneu.2022.12.052"},{"issue":"2","key":"b18","series-title":"J Neurosurg","first-page":"533","article-title":"Patterns of recurrence according to the extent of resection in patients with IDH\u2013wild-type glioblastoma: a retrospective study","volume":"137","author":"Yoo J","year":"2022","unstructured":"Yoo J, Yoon SJ, Kim KH,  Patterns of recurrence according to the extent of resection in patients with IDH\u2013wild-type glioblastoma: a retrospective study. J Neurosurg. 2022;137(2):533\u2013543. doi:10.3171\/2021.10.JNS211491"},{"issue":"10","key":"b19","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp R","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ,  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u2013996. doi:10.1056\/NEJMoa043330"},{"issue":"11","key":"b20","series-title":"N Engl J Med","first-page":"1027","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry JR","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ,  Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027\u20131037. doi:10.1056\/NEJMoa1611977"},{"issue":"4","key":"b21","series-title":"J Neurosurg","first-page":"977","article-title":"The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?","volume":"124","author":"Li YM","year":"2016","unstructured":"Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection?. J Neurosurg. 2016;124(4):977\u2013988. doi:10.3171\/2015.5.JNS142087"},{"issue":"282","key":"b22","series-title":"J Amer Stat Assoc","first-page":"457","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc. 1958;53(282):457\u2013481. doi:10.1080\/01621459.1958.10501452"},{"issue":"2","key":"b23","series-title":"JR Stat Soc Series B Stat Methodol","first-page":"187","article-title":"Regression models and life-tables","volume":"34","author":"Cox DR","year":"1972","unstructured":"Cox DR. Regression models and life-tables. JR Stat Soc Series B Stat Methodol. 1972;34(2):187\u2013202. doi:10.1111\/j.2517-6161.1972.tb00899.x"}],"container-title":["Journal of Neurosurgery"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2026.1.JNS25467\/article-10.3171-2026.1.JNS25467.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2026.1.JNS25467\/article-10.3171-2026.1.JNS25467.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/j-neurosurg\/aop\/article-10.3171-2026.1.JNS25467\/article-10.3171-2026.1.JNS25467.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:35:39Z","timestamp":1787967339000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/j-neurosurg\/aop\/article-10.3171-2026.1.JNS25467\/article-10.3171-2026.1.JNS25467.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":23,"URL":"https:\/\/doi.org\/10.3171\/2026.1.jns25467","relation":{},"ISSN":["0022-3085","1933-0693"],"issn-type":[{"value":"0022-3085","type":"print"},{"value":"1933-0693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}